Kura Oncology Reports Q2 2026 Results and Corporate Update

What Happened
Kura Oncology, Inc. announced its financial results for the quarter ended June 30, 2026 and provided a corporate update by issuing a press release on August 12, 2026. The company furnished that press release to the SEC as Exhibit 99.1 in a Form 8-K (Item 2.02), disclosing its quarterly results and related corporate information.

Key Details

• Filing date: August 12, 2026.
• Period covered: Quarter ended June 30, 2026 (Q2 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K was signed by Teresa Bair, Chief Legal Officer, on behalf of Kura Oncology.

Why It Matters
This 8-K signals that Kura has publicly released its quarterly financial results and accompanying corporate update; investors should review the furnished press release for revenue, earnings, guidance, and program updates. For full audited financial statements, management discussion and analysis, and any changes to outlook or governance, watch for the company’s upcoming 10-Q and subsequent SEC filings.